BCYC Profile
Bicycle Therapeutics Plc (BCYC) is a clinical-stage biopharmaceutical company focused on the development of innovative medicines designed to address significant unmet medical needs. The company's proprietary bicyclic peptide (Bicycle) technology platform is capable of creating small molecules with antibody-like selectivity and affinity. These Bicycle molecules can be used to treat a broad range of diseases, including cancer, central nervous system disorders, and other therapeutic areas.
Bicycle Therapeutics' lead program is BT1718, a Bicycle Toxin Conjugate (BTC) that targets Membrane Type 1 Matrix Metalloprotease (MT1-MTP), a protein that is overexpressed in several solid tumor types. The company is also developing other Bicycle Toxin Conjugates, Bicycle Peptide Conjugates, and Bicycle Immune Cell Conjugates.
The company is headquartered in Cambridge, UK, and has operations in the United States. Bicycle Therapeutics is publicly traded on the NASDAQ stock exchange under the ticker symbol BCYC.
|
